Mdxhealth Sa

1.1600-0.2500-17.73%Vol 3.00K1Y Perf 36.47%
Nov 8th, 2021 20:10
BID0.0000 ASK0.0000
Open1.1600 Previous Close1.4100
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     41.34
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
24.39 
Earnings Rating
Market Cap81.81M 
Earnings Date
-
Alpha-0.02 Standard Deviation0.16
Beta0.97 

Today's Price Range

1.16001.1600

52W Range

0.96001.7800

5 Year PE Ratio Range

-8.7000-1.9000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-21.62%
3 Months
-15.95%
6 Months
-34.83%
1 Year
36.47%
3 Years
-42.29%
5 Years
-
10 Years
0.00%

TickerPriceChg.Chg.%
MXDHF1.1600-0.2500-17.73
AAPL156.81-5.1300-3.17
GOOG2 856.12-78.2300-2.67
MSFT329.68-8.2300-2.44
XOM61.25-2.2300-3.51
WFC48.43-2.8800-5.61
JNJ159.20-1.0400-0.65
FB333.12-7.9400-2.33
GE97.84-4.3900-4.29
JPM161.93-5.0300-3.01
Financial StrengthValueIndustryS&P 500US Markets
2.60
3.20
0.35
0.70
-18.00
Leverage Ratio 6.60
ProfitabilityValueIndustryS&P 500US Markets
43.60
-139.20
-122.70
-718.00
-
RevenueValueIndustryS&P 500US Markets
19.22M
0.12
-1.92
-4.75
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume3.00K
Shares Outstanding70.53M
Shares Float155.97M
Trades Count1
Dollar Volume49
Avg. Volume18.88K
Avg. Weekly Volume3.38K
Avg. Monthly Volume16.35K
Avg. Quarterly Volume3.13K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Mdxhealth Sa

MDxHealth SA is a multinational healthcare company. It develops and commercializes advanced epigenetic and other molecular tests to personalize the diagnosis and treatment of cancer. The firm's tests are based on proprietary genetic and epigenetic and other molecular technologies and assist physicians and the diagnosis of urologic cancers, the prognosis of recurrence risk and prediction of response to a specific therapy. Its product pipeline covers major cancer areas such as prostate, bladder, kidney, cervical and brain cancer. The company derives its revenues from the sale of clinical laboratory testing services, technology out-licensing deals, research and development service fees, and government grants. Geographically, it derives majority revenue from the United States of America.

CEO:

Telephone: +32 42577021

Address: Rue d'Abhooz, 31, Herstal 4040, , BEL

Number of employees: 187

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

40%60%

Bearish Bullish

40%60%

News